Compare ASMB & IBEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | IBEX |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 489.1M |
| IPO Year | 2010 | 2017 |
| Metric | ASMB | IBEX |
|---|---|---|
| Price | $28.40 | $30.32 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $43.40 | $35.00 |
| AVG Volume (30 Days) | 93.3K | ★ 142.3K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | 28.26 |
| EPS | N/A | ★ 1.65 |
| Revenue | N/A | ★ $558,273,000.00 |
| Revenue This Year | $33.33 | $13.14 |
| Revenue Next Year | N/A | $5.67 |
| P/E Ratio | ★ N/A | $18.46 |
| Revenue Growth | N/A | ★ 9.77 |
| 52 Week Low | $7.76 | $21.64 |
| 52 Week High | $39.71 | $42.99 |
| Indicator | ASMB | IBEX |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 43.52 |
| Support Level | $26.50 | $27.70 |
| Resistance Level | $31.11 | $30.63 |
| Average True Range (ATR) | 1.84 | 1.00 |
| MACD | 0.11 | 0.38 |
| Stochastic Oscillator | 57.55 | 90.09 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.